VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half of in sufferers with immunoglobulin A (IgA) nephropathy, in holding with an period in-between prognosis of the VISIONARY trial. Previous this clinical attain, a important commentary was the lack of security considerations…
Read Extra
2025-06-09
